Filing Flows › Cardio Diagnostics Holdings (CDIO) › R&D spending
Cardio Diagnostics Holdings (CDIO) R&D spending by quarter
Cardio Diagnostics Holdings' R&D spending was $174K in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 5 quarters it ranged from $2K (Q1 2025) to $287K (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $174K | +7% | — |
| Q2 2026 | $163K | +26% | — |
| Q1 2026 | $130K | -55% | 59× |
| Q4 2025 | $287K | 130× | — |
| Q1 2025 | $2K | — | — |
Q3 2026 at a glance
Cardio Diagnostics Holdings, Q3 2026: revenue $4K (+26% year over year), net loss $1.7M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Cardio Diagnostics Holdings' R&D spending?
Cardio Diagnostics Holdings' R&D spending was $174K in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Cardio Diagnostics Holdings' R&D spending changed?
Over the last 5 quarters it ranged from $2K (Q1 2025) to $287K (Q4 2025).
Q3 2026 results → · How Cardio Diagnostics Holdings makes money →